Skip to content
BoardCited

Cardiovascular, renal and endocrine medications

3 free NCLEX-RN practice questions on this topic, with the answer, a reason for every option and the source. The full bank has 45 questions here.

Question 1Single answer

The nurse is teaching a client who will take warfarin at home after treatment for a pulmonary embolism. Which statement by the client indicates a need for further teaching?

  1. A"I will check with my provider before I start any herbal supplement."
  2. B"I will stop eating salads and green vegetables completely."
  3. C"I will keep every appointment for my INR blood test."
  4. D"I will call if I notice a painful, darkening area on my skin."
Show answer and sources

Answer: B. "I will stop eating salads and green vegetables completely."

Warfarin teaching stresses a consistent vitamin K intake, not avoidance of green vegetables; the other statements reflect correct monitoring and reporting.

  • A. Correct: starting or stopping drugs, including botanicals, requires more frequent INR monitoring.
  • B. Clients on warfarin should keep a normal, balanced diet with a consistent vitamin K intake rather than eliminating leafy greens.
  • C. Correct: regular INR monitoring is required for every client taking warfarin.
  • D. Correct: warfarin can cause skin necrosis, which must be reported.
  1. [1] FDA label (DailyMed): WARFARIN SODIUM TABLET [REMEDYREPACK INC.] . FDA label, 17 Patient Counseling; FDA label, Boxed Warning; FDA label, 5 Warnings and Precautions, Tissue necrosis
  2. [2] Nursing Pharmacology, 2nd edition . Ch 6 Blood Coagulation Modifiers, Warfarin
Question 2Single answer

A client receiving a continuous IV heparin infusion for a pulmonary embolism has an aPTT of 52 seconds. The laboratory control value is 30 seconds. The client has no signs of bleeding. Which action should the nurse take?

  1. AContinue the infusion at the current rate and recheck the aPTT as scheduled
  2. BStop the infusion and notify the HCP of a critical value
  3. CRequest an order for protamine sulfate
  4. DIncrease the infusion rate to reach an aPTT above 75 seconds
Show answer and sources

Answer: A. Continue the infusion at the current rate and recheck the aPTT as scheduled

IV heparin is adequate when the aPTT is 1.5 to 2 times normal (45 to 60 seconds with a 30-second control), so the infusion continues unchanged.

  • A. 52 seconds is about 1.7 times the control, within the therapeutic 1.5 to 2 times normal range.
  • B. The value is therapeutic, not excessive; stopping the infusion would leave the clot untreated.
  • C. Protamine is for heparin overdose or bleeding, neither of which is present.
  • D. An aPTT of 75 seconds would exceed 2 times the control and raise bleeding risk.
  1. [1] FDA label (DailyMed): HEPARIN SODIUM INJECTION [GLAND PHARMA LIMITED] . FDA label, 2 Dosage and Administration
  2. [2] Nursing Pharmacology, 2nd edition . Ch 6 Heparin Sodium
Question 3Single answer

A client has been receiving IV heparin for 7 days. The platelet count was 240,000/mm3 on admission and is 85,000/mm3 today. Which action should the nurse take?

  1. AContinue the infusion because day 7 is too early for heparin-related platelet changes
  2. BContinue the infusion and recheck the platelet count tomorrow
  3. CStop the heparin infusion and notify the HCP promptly
  4. DReduce the infusion rate by half and continue to monitor
Show answer and sources

Answer: C. Stop the heparin infusion and notify the HCP promptly

Heparin should be promptly discontinued if the platelet count falls below 100,000/mm3; the onset on day 7 fits heparin-associated thrombocytopenia.

  • A. Heparin-associated thrombocytopenia can appear 2 to 20 days after starting, averaging 5 to 9 days.
  • B. Waiting allows thrombocytopenia and possible thrombosis to progress.
  • C. A fall below 100,000/mm3 during heparin therapy calls for prompt discontinuation; day 7 fits the usual timing of heparin-associated thrombocytopenia.
  • D. Dose reduction is not the response to a platelet count below 100,000/mm3; heparin should be stopped.
  1. [1] FDA label (DailyMed): HEPARIN SODIUM INJECTION [GLAND PHARMA LIMITED] . FDA label, 5 Warnings and Precautions, Thrombocytopenia

Practise all 45 questions on this topic

Tutor mode, timed blocks and progress tracking.

Start free